• Disc Medicine posted a wider Q2 net loss of USD 59.53 million, compared with a loss of USD 55.25 million a year earlier.
• R&D spending rose to USD 46.93 million from USD 46.32 million, due to advancing selcodebart and DISC-3405 studies, manufacturing, and higher headcount.
• SG&A expenses climbed to USD 18.14 million from USD 15.09 million on increased headcount.
• Cash, cash equivalents and marketable securities fell to USD 717.75 million at June 30, 2026, from USD 791.15 million at end-2025; runway projected into 2029.
• Bitopertin Phase 3 APOLLO topline data remains due in Q4 2026, with an FDA decision on a CRL response targeted for mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300830PRIMZONEFULLFEED9800763) on July 30, 2026, and is solely responsible for the information contained therein.